Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(162 prodotti)
- Bcr-Abl(117 prodotti)
- EGFR(593 prodotti)
- FAK(72 prodotti)
- FLT(90 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(183 prodotti)
- JAK(247 prodotti)
- PDGFR(127 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(53 prodotti)
- VDA(2 prodotti)
- VEGFR(245 prodotti)
Mostrare 6 più sottocategorie
Trovati 2156 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Gefitinib N-oxide
CAS:Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.Formula:C22H24ClFN4O4Purezza:98%Colore e forma:SolidPeso molecolare:462.9TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Formula:C29H31F3N8OPurezza:98%Colore e forma:SolidPeso molecolare:564.6EGFR-IN-88
CAS:EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosisFormula:C22H18Cl2N4O2SPurezza:98%Colore e forma:SolidPeso molecolare:473.37BAY 2476568
CAS:BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).Formula:C24H27FN4O4Colore e forma:SolidPeso molecolare:454.49FGFR4-IN-5
CAS:FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.Formula:C23H23Cl2N5O5Colore e forma:SolidPeso molecolare:520.37DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formula:C25H26ClN7O3Colore e forma:SolidPeso molecolare:507.97PDGFRα/FLT3-ITD-IN-1
CAS:PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.Formula:C27H39N9OColore e forma:SolidPeso molecolare:505.66EGFR-IN-89
CAS:EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM againstFormula:C26H31FN8O2SPurezza:98%Colore e forma:SolidPeso molecolare:538.64KRC-108
CAS:KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.Formula:C20H20N6OColore e forma:SolidPeso molecolare:360.41PF-00337210
CAS:PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.Formula:C26H27N3O5Colore e forma:SolidPeso molecolare:461.51YF-452
CAS:YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Formula:C24H26BrN3OPurezza:98%Colore e forma:SolidPeso molecolare:452.39Multi-kinase-IN-3
CAS:Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).Formula:C33H33N5O3Colore e forma:SolidPeso molecolare:547.65VEGFR-2-IN-30
VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.Formula:C28H23ClN6O4S2Colore e forma:SolidPeso molecolare:607.1VEGFR-2-IN-20
CAS:VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].Formula:C20H20N4O3SColore e forma:SolidPeso molecolare:396.46VEGFR-2-IN-21
CAS:VEGFR-2-IN-21 is a potent inhibitor of VEGFR-2 (IC50: 0.10 μM) and exhibits anticancer effects.Formula:C28H24ClN7O3SColore e forma:SolidPeso molecolare:574.05VEGFR-2-IN-22
CAS:VEGFR-2-IN-22 blocks VEGFR-2/beta-tubulin, IC50=19.82 nM, induces apoptosis.Formula:C26H24ClFN4O6Colore e forma:SolidPeso molecolare:542.94Depatuxizumab mafodotin
CAS:Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].Colore e forma:LiquidSYK/JAK-IN-1
CAS:SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.Formula:C24H26N8O3Colore e forma:SolidPeso molecolare:474.52FGFR-IN-7
CAS:FGFR-IN-7: Oral FGFR modulator, crosses blood-brain barrier, neuroprotective, phospholipidosis-resistant, useful for neurodegeneration study.Formula:C16H21ClF2N4O2Colore e forma:SolidPeso molecolare:374.81EMI56
CAS:EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].Formula:C21H20N2O3Colore e forma:SolidPeso molecolare:348.4
